These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28732516)

  • 1. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
    Choi HS; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH; Kang KM
    Radiat Oncol; 2017 Jul; 12(1):122. PubMed ID: 28732516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Chen NB; Li QW; Zhu ZF; Wang YM; Cheng ZJ; Hui ZG; Guo SP; He HQ; Wang B; Huang XY; Li JB; Guo JY; Hu N; Ai XL; Zhou Y; Wang DQ; Liu FJ; Xie CM; Qiu B; Liu H
    Radiat Oncol; 2020 Nov; 15(1):260. PubMed ID: 33168045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.
    Oh D; Ahn YC; Park HC; Lim DH; Noh JM; Cho WK; Pyo H
    Oncotarget; 2017 May; 8(22):35700-35706. PubMed ID: 28415687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC.
    Shang X; Liu J; Li Z; Lin J; Wang H
    BMC Cancer; 2019 Jun; 19(1):591. PubMed ID: 31208403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.
    Sakin A; Sahin S; Atci MM; Sakin A; Yasar N; Geredeli C; Aksaray F; Cihan S
    Pulmonology; 2021; 27(1):26-34. PubMed ID: 31839507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small-cell lung cancer.
    Kato M; Onishi H; Matsumoto K; Tsuruta N; Higuchi K; Motoshita J; Katano M
    Anticancer Res; 2012 Nov; 32(11):5099-104. PubMed ID: 23155287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
    Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Validity and controversies in the new postoperative pathologic TNM classification based on the results of surgical treatment of non-small cell lung cancer].
    Hosokawa Y; Matsuge S; Murakami Y; Satoh K; Yamazaki S; Kan T; Hatakeyama H
    Kyobu Geka; 2000 Oct; 53(11):910-4. PubMed ID: 11048440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    Haro GJ; Sheu B; Cook NR; Woodard GA; Mann MJ; Kratz JR
    JAMA Netw Open; 2019 Dec; 2(12):e1917062. PubMed ID: 31808928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
    Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
    Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
    Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
    Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External Validation of the New International Association for the Study of Lung Cancer Tumor, Node, and Metastasis 8th Edition Staging System and Updated T Descriptors in Determining Prognosis for Patients With Non-Small Cell Lung Cancer Patients With N3 Disease.
    Shin JY; Yoon JK; Marwaha G
    Clin Lung Cancer; 2017 Nov; 18(6):e481-e489. PubMed ID: 28559200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
    Lim HJ; Lee HY; Lee KS; Han J; Kwon OJ; Park K; Ahn YC; Kim BT; Shim YM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):77-85. PubMed ID: 25374409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non-small-cell Lung Cancer.
    Chen K; Chen H; Yang F; Sui X; Li X; Wang J
    Clin Lung Cancer; 2017 Nov; 18(6):e457-e466. PubMed ID: 28539214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.